| Outcome Measures: |
Primary: Change in glycohemoglobin(HbA1c) from baseline, baseline, 24 weeks | Secondary: Proportion of subjects achieving HbA1c < 7.0%, 24 week|Proportion of subjects achieving HbA1c <6.5%, 24 week|Changes in glycated albumin(GA) from baseline, baseline, 24 weeks|Change in GA/HbA1c ratio from baseline, baseline, 24 weeks|Change in fasting blood sugar from baseline, baseline, 24 weeks|Incidence of hyperglycemic rescue, at Week 12, HbA1c \>9.0%, 12 week|Change in HbA1c from baseline, 12 week|Change in total cholesterol from baseline, baseline, 24 weeks|Change in triglycerides from baseline, baseline, 24 weeks|Change in LDL-cholesterol from baseline, baseline, 24 weeks|Change in HDL-cholesterol from baseline, baseline, 24 weeks|Changes in glycated albumin(GA) from baseline, baseline, 12 weeks|Change in GA/HbA1c ratio from baseline, baseline, 12 weeks|Change in fasting blood sugar from baseline, baseline, 12 weeks|Change in total cholesterol from baseline, baseline, 12 weeks|Change in triglycerides from baseline, baseline, 12 weeks|Change in LDL-cholesterol from baseline, baseline, 12 weeks|Change in HDL-cholesterol from baseline, baseline, 12 weeks|Change in Homeostasis Model Assessment-Insulin resistance(HOMA-IR) from baseline, a marker of insulin resistance, baseline, 24 weeks|Change in Homeostasis Model Assessment - beta cell (HOMA-beta) from baseline, a marker of beta cell function, baseline, 24 weeks|Change in highly sensitive C reactive protein(hs-CRP) from baseline, a marker of inflammation, baseline, 24 weeks|Change in Plasmonogen activator inhibitor-1(PAI-1) from baseline, baseline, 24 weeks|Change in B-type natriuretic pepetide(BNP) from baseline, baseline, 24 weeks|event rate of hypoglycemia, A number of total event of hypoglycemia defined as blood glucose \<70mg/dL or subjective symptom of typical hypoglycemia, upto 24 weeks|No of subject with adverse event of special interest, The event of special interest include * heart failure * cardiovascular effect other than heart failure * edema * weight gain * urinary bladder tumor * macular edema * fracture of bone * pancreatitis, upto 24 weeks|The number of serious adverse events, upto 24 weeks|The number of subject with hypersensitivity to study drugs, upto 24 weeks|The number of subject with any abnormality of laboratory evaluation, * Complete Blood count * BUN, Creatinine, AST, ALT, Calcium, Phosphorous, Sodium, Potassium, Total Protein, Albumin, Total Bilirubin, Gamma-glutamyl transferase, Alkaline phosphatase, Creatinine Kinase, amylase, lipase * Urine analysis including microscopic examination, 12 week|The number of subject with any abnormality of laboratory evaluation, * Complete Blood count * Blood urea nigrogen, Creatinine, Aspartate aminotransferase, Alanine Aminotransferase, Calcium, Phosphorous, Sodium, Potassium, Total Protein, Albumin, Total Bilirubin, Gamma-glutamyl transferase, Alkaline phosphatase, Creatinine Kinase, amylase, lipase * Urine analysis including microscopic examination, 24 week|The number of subject with any change of findings in Chest X-ray from baseline, 24 week|The number of subject with any change of findings in electrocardiogram from baseline, 24 week
|
